Appendix A

References

Agüera, Z., M. Lozano-Madrid, N. Mallorquí-Bagué, S. Jiménez-Murcia, J. M. Menchón, and F. Fernández-Aranda. 2021. A review of binge eating disorder and obesity. Neuropsychiatry 35(2):57–67.

Allison, K. C., A. M. Chao, M. B. Bruzas, C. McCuen-Wurst, E. Jones, C. McAllister, K. Gruber, R. I. Berkowitz, T. A. Wadden, and J. S. Tronieri. 2022. A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder. Obesity Science and Practice 9(2):127–136.

Aoun, L., S. Almardini, F. Saliba, F. Haddadin, O. Mourad, J. Jdaidani, Z. Morcos, I. Al Saidi, E. Bou Sanayeh, S. Saliba, M. Almardini, and J. Zaidan. 2024. GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (binge eating disorder and bulimia nervosa)? A systematic review. Journal of Clinical & Translational Endocrinology 35:100333.

Aranäs, C., C. E. Edvardsson, O. T. Shevchouk, Q. Zhang, S. Witley, S. Blid Sköldheden, L. Zentveld, D. Vallöf, M. Tufvesson-Alm, and E. Jerlhag. 2023. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine 93:104642.

Aronne, L. J., N. Sattar, D. B. Horn, H. E. Bays, S. Wharton, W.-Y. Lin, N. N. Ahmad, S. Zhang, R. Liao, and M. C. Bunck. 2024. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The surmount-4 randomized clinical trial. JAMA 331(1):38–48.

Ashraf, A. R., T. K. Mackey, J. Schmidt, G. Kulcsár, R. G. Vida, J. Li, and A. Fittler. 2024. Safety and risk assessment of no-prescription online semaglutide purchases. JAMA Network Open 7(8):e2428280.

Athauda, D., K. Maclagan, S. S. Skene, M. Bajwa-Joseph, D. Letchford, K. Chowdhury, S. Hibbert, N. Budnik, L. Zampedri, J. Dickson, Y. Li, I. Aviles-Olmos, T. T. Warner, P. Limousin, A. J. Lees, N. H. Greig, S. Tebbs, and T. Foltynie. 2017. Exenatide once weekly versus placebo in Parkinson’s disease: A randomised, double-blind, placebo-controlled trial. The Lancet 390(10103):1664–1675.

Athauda, D., K. Maclagan, N. Budnik, L. Zampedri, S. Hibbert, S. S. Skene, K. Chowdhury, I. Aviles-Olmos, P. Limousin, and T. Foltynie. 2018. What effects might exenatide have on non-motor symptoms in Parkinson’s disease: A post hoc analysis. Journal of Parkinson’s Disease 8(2):247–258.

Athauda, D., S. Gulyani, H. K. Karnati, Y. Li, D. Tweedie, M. Mustapic, S. Chawla, K. Chowdhury, S. S. Skene, N. H. Greig, D. Kapogiannis, and T. Foltynie. 2019. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: A secondary analysis of the Exenatide-PD Trial. JAMA Neurology 76(4):420–429.

Aviles-Olmos, I., J. Dickson, Z. Kefalopoulou, A. Djamshidian, P. Ell, T. Soderlund, P. Whit-ton, R. Wyse, T. Isaacs, A. Lees, P. Limousin, and T. Foltynie. 2013. Exenatide and the treatment of patients with Parkinson’s disease. Journal of Clinical Investigations 123(6):2730–2736.

Balantekin, K. N., M. J. Kretz, and E. G. Mietlicki-Baase. 2024. The emerging role of glucagon-like peptide 1 in binge eating. Journal of Endocrinology 262(1):e230405.

Barrera, J. G., K. R. Jones, J. P. Herman, D. A. D’Alessio, S. C. Woods, and R. J. Seeley. 2011. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. Journal of Neuroscience 31(10):3904–3913.

Boileau, I., J. M. Assaad, R. O. Pihl, C. Benkelfat, M. Leyton, M. Diksic, R. E. Tremblay, and A. Dagher. 2003. Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 49(4):226–231.

Botfield, H. F., M. S. Uldall, C. S. J. Westgate, J. L. Mitchell, S. M. Hagen, A. M. Gonzalez, D. J. Hodson, R. H. Jensen, and A. J. Sinclair. 2017. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Science Translational Medicine 9(404):eaan0972.

Brauer, R., L. Wei, T. Ma, D. Athauda, C. Girges, N. Vijiaratnam, G. Auld, C. Whittlesea, I. Wong, and T. Foltynie. 2020. Diabetes medications and risk of Parkinson’s disease: A cohort study of patients with diabetes. Brain 143(10):3067–3076.

Brierley, D. I., M. K. Holt, A. Singh, A. de Araujo, M. McDougle, M. Vergara, M. H. Afaghani, S. J. Lee, K. Scott, C. Maske, W. Langhans, E. Krause, A. de Kloet, F. M. Gribble, F. Reimann, L. Rinaman, G. de Lartigue, and S. Trapp. 2021. Central and peripheral GLP-1 systems independently suppress eating. Nature Metabolism 3(2):258–273.

Bruns, N., VI, E. H. Tressler, L. F. Vendruscolo, L. Leggio, and M. Farokhnia. 2024. IUPHAR review—Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacological Research 207:107312.

Campbell, J. E., T. D. Müller, B. Finan, R. D. DiMarchi, M. H. Tschöp, and D. A. D’Alessio. 2023. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—Chemistry, physiology, and clinical applications. Cell Metabolism 35(9):1519–1529.

Card, J. P., A. L. Johnson, I. J. Llewellyn-Smith, H. Zheng, R. Anand, D. I. Brierley, S. Trapp, and L. Rinaman. 2018. GLP-1 neurons form a local synaptic circuit within the rodent nucleus of the solitary tract. Journal of Comparative Neurology 526(14):2149–2164.

Chang, M. 2022. Despite failing phase 2a clinical trials, Peptron not giving up on Parkinson’s treatment. Korea Biomedical Review, December 22. https://www.koreabiomed.com/news/articleView.html?idxno=20071 (accessed September 22, 2024).

Chen, W.-H., Y. Li, L. Yang, J. M. Allen, H. Shao, W. T. Donahoo, L. Billelo, X. Hu, E. A. Shenkman, and J. Bian. 2024. Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes. Plos One 19(1):e0297208.

Christensen, M., A. H. Sparre-Ulrich, B. Hartmann, U. Grevstad, M. M. Rosenkilde, J. J. Holst, T. Vilsbøll, and F. K. Knop. 2015. Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. International Journal of Obesity (London) 39(11):1651–1654.

Chuong, V., M. Farokhnia, S. Khom, C. L. Pince, S. K. Elvig, R. Vlkolinsky, R. C. Marchette, G. F. Koob, M. Roberto, L. F. Vendruscolo, and L. Leggio. 2023. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight 8(12):e170671.

Cleveland, H. H., K. S. Knapp, T. R. Brick, M. A. Russell, J. M. Gajos, and S. C. Bunce. 2021. Effectiveness and utility of mobile device assessment of subjective craving during residential opioid dependence treatment. Substance Use & Misuse 56(9):1284–1294.

Collins, L., and R. A. Costello. 2019. Glucagon-like peptide-1 receptor agonists. Treasure Island, FL: StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK551568/ (accessed November 27, 2024).

Concato, J., and J. Corrigan-Curay. 2022. Real-world evidence—Where are we now? New England Journal of Medicine 386(18):1680–1682.

Deloitte Access Economics. 2020. The social and economic cost of eating disorders in the United States of America: A report for the Strategic Training Initiative for the Prevention of Eating Disorders and the Academy for Eating Disorders. Available at: https://www.hsph.harvard.edu/striped/report-economic-costs-of-eating-disorders/ (accessed September 26, 2024).

Doucleff, M. 2023. Ozempic seems to curb cravings for alcohol. Here’s what scientists think is going on. NPR News, August 28. https://www.npr.org/sections/health-shots/2023/08/28/1194526119/ozempic-wegovy-drinking-alcohol-cravings-semaglutide (accessed October 1, 2024).

Douton, J. E., N. K. Acharya, B. Stoltzfus, D. Sun, P. S. Grigson, and J. E. Nyland. 2022. Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats. Behavioral Pharmacology 33(5):364–378.

Drucker, D. J. 2022. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism 57:101351.

Drucker, D. J. 2024. The benefits of GLP-1 drugs beyond obesity. Science 385(6706):258–260.

Drucker, D. J., and J. J. Holst. 2023. The expanding incretin universe: From basic biology to clinical translation. Diabetologia 66(10):1765–1779.

Drucker, D. J., J. Philippe, S. Mojsov, W. L. Chick, and J. F. Habener. 1987. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic amp levels in a rat islet cell line. Proceedings of the National Academy of Sciences 84(10):3434–3438.

During, M. J., L. Cao, D. S. Zuzga, J. S. Francis, H. L. Fitzsimons, X. Jiao, R. J. Bland, M. Klugmann, W. A. Banks, and D. J. Drucker. 2003. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature Medicine 9(9):1173–1179.

Egecioglu, E., P. Steensland, I. Fredriksson, K. Feltmann, J. A. Engel, and E. Jerlhag. 2013. The glucagon-like peptide 1 analogue exendin-4 attenuates alcohol mediated behaviors in rodents. Psychoneuroendocrinology 38(8):1259–1270.

Evans, B., B. Stoltzfus, N. Acharya, J. E. Nyland, A. C. Arnold, C. S. Freet, S. C. Bunce, and P. S. Grigson. 2022. Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats. Brain Research Bulletin 189:163–173.

Fang, J., P. Miller, and P. S. Grigson. 2023. Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats. Brain Research Bulletin 192:142–155.

Farkas, E., A. Szilvásy-Szabó, Y. Ruska, R. Sinkó, M. G. Rasch, T. Egebjerg, C. Pyke, B. Gereben, L. B. Knudsen, and C. Fekete. 2021. Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain. Brain Structure and Function 226(1):225–245.

FDA-NIH (Food and Drug Administration and National Institutes of Health) Biomarker Working Group. n.d. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring, MD: Food and Drug Administration. https://www.ncbi.nlm.nih.gov/books/NBK326791/ (accessed September 22, 2024).

Femminella, G. D., E. Frangou, S. B. Love, G. Busza, C. Holmes, C. Ritchie, R. Lawrence, B. McFarlane, G. Tadros, B. H. Ridha, C. Bannister, Z. Walker, H. Archer, E. Coulthard, B. R. Underwood, A. Prasanna, P. Koranteng, S. Karim, K. Junaid, B. McGuinness, R. Nilforooshan, A. Macharouthu, A. Donaldson, S. Thacker, G. Russell, N. Malik, V. Mate, L. Knight, S. Kshemendran, J. Harrison, C. Hölscher, D. J. Brooks, A. P. Passmore, C. Ballard, and P. Edison. 2019. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: Study protocol for a randomised controlled trial (ELAD study). Trials 20(1):191.

Feng, P., X. Zhang, D. Li, C. Ji, Z. Yuan, R. Wang, G. Xue, G. Li, and C. Hölscher. 2018. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson’s disease. Neuropharmacology 133:385–394.

Gabery, S., C. G. Salinas, S. J. Paulsen, J. Ahnfelt-Rønne, T. Alanentalo, A. F. Baquero, S. T. Buckley, E. Farkas, C. Fekete, K. S. Frederiksen, H. C. C. Helms, J. F. Jeppesen, L. M. John, C. Pyke, J. Nøhr, T. T. Lu, J. Polex-Wolf, V. Prevot, K. Raun, L. Simonsen, G. Sun, A. Szilvásy-Szabó, H. Willenbrock, A. Secher, L. B. Knudsen, and W. F. J. Hogendorf. 2020. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5(6):e133429.

Garvey, W. T., J. I. Mechanick, E. M. Brett, A. J. Garber, D. L. Hurley, A. M. Jastreboff, K. Nadolsky, R. Pessah-Pollack, and R. Plodkowski. 2016. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice 22(Suppl 3):1–203.

Glanz, K., J. F. Sallis, B. E. Saelens, and L. D. Frank. 2005. Healthy nutrition environments: Concepts and measures. American Journal of Health Promotion 19(5):330–333, ii.

Glanz, K., S. Murphy, J. Moylan, D. Evensen, and J. D. Curb. 2006. Improving dietary self-monitoring and adherence with hand-held computers: A pilot study. American Journal of Health Promotion 20(3):165–170.

Glanz, K., P. A. Shaw, P. L Kwong, J. R. Choi, A. Chung, J. Zhu, Q. E. Huang, K. Hoffer, and K. G. Volpp. 2021. Effect of financial incentives and environmental strategies on weight loss in the Healthy Weigh Study: A randomized clinical trial. JAMA Network Open 4(9):e2124132.

Glanz, K., A. K. Fultz, J. F. Sallis, M. Clawson, K. C. McLaughlin, S. Green, and B. E. Saelens. 2023. Use of the Nutrition Environment Measures Survey: A systematic review. American Journal of Preventive Medicine 65(1):131–142.

Gu, G., B. Roland, K. Tomaselli, C. S. Dolman, C. Lowe, and J. S. Heilig. 2013. Glucagon-like peptide-1 in the rat brain: Distribution of expression and functional implication. Journal of Comparative Neurology 521(10):2235–2261.

Hallaj, S., W. Halfpenny, B. G. Chuter, R. N. Weinreb, S. L. Baxter, Q. N. Cui. 2025. Association between glucagon-like peptide 1 (GLP-1) receptor agonists exposure and intraocular pressure change. American Journal of Ophthalmology 269:255–265. https://doi.org/10.1016/j.ajo.2024.08.030.

Halloum, W., Y. A. Dughem, D. Beier, and L. Pellesi. 2024. Glucagon-like peptide-1 (GLP1) receptor agonists for headache and pain disorders: A systematic review. Journal of Headache and Pain 25(1):112.

Heilig, M., J. MacKillop, D. Martinez, J. Rehm, L. Leggio, and L. J. M. J. Vanderschuren. 2021. Addiction as a brain disease revised: Why it still matters, and the need for consilience. Neuropsychopharmacology 46:1715–1723.

Hernandez, N. S., and H. D. Schmidt. 2019. Central GLP-1 receptors: Novel molecular targets for cocaine use disorder. Physiology & Behavior 206:93–105.

Hernandez, N. S., K. Y. Ige, E. G. Mietlicki-Baase, G. C. Molina-Castro, C. A. Turner, M. R. Hayes, and H. D. Schmidt. 2018. Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats. Neuropsychopharmacology 43(10):2000–2008.

Hernandez, N. S., V. R. Weir, K. Ragnini, R. Merkel, Y. Zhang, K. Mace, M. T. Rich, R. Christopher Pierce, and H. D. Schmidt. 2021. GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA. Molecular Psychiatry 26(8):4394–4408.

Hinnen, D. 2017. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectrum 30(3):202–210.

Hölscher, C. 2022. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. British Journal of Pharmacology 179(4):695–714.

Holt, M. K., J. E. Richards, D. R. Cook, D. I. Brierley, D. L. Williams, F. Reimann, F. M. Gribble, and S. Trapp. 2019. Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP-1, mediate stress-induced hypophagia, and limit unusually large intakes of food. Diabetes 68(1):21–33.

Huang, K. P., A. A. Acosta, M. Y. Ghidewon, A. D. McKnight, M. S. Almeida, N. T. Nyema, N. D. Hanchak, N. Patel, Y. S. K. Gbenou, A. E. Adriaenssens, K. A. Bolding, and A. L. Alhadeff. 2024. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature 632(8025):585–593.

Hudson, J. I., E. Hiripi, H. G. Pope Jr., and R. C. Kessler. 2007. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biological Psychiatry 61(3):348–358. Erratum in: Biological Psychiatry 72(2):164.

Jastreboff, A. M., L. J. Aronne, N. N. Ahmad, S. Wharton, L. Connery, B. Alves, A. Kiyosue, S. Zhang, B. Liu, and M. C. Bunck. 2022. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine 387(3):205–216.

Jerlhag, E. 2023. The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies. Frontiers in Pharmacology 14:1063033.

Jia, Y., N. Gong, T.-F. Li, B. Zhu, and Y.-X. Wang. 2015. Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway. Pharmacological Research 102:276–285.

Jing, F., Q. Zou, Y. Wang, Z. Cai, and Y. Tang. 2021. Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation. Journal of Headache and Pain 22(1):86.

Jing, F., Q. Zou, and Y. Pu. 2023. GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model. Neuroscience Letters 812:137397.

Johnson, A. 2024. Increasing evidence suggests Ozempic (semaglutide) helps curb alcoholism. Forbes, June 5. https://www.forbes.com/sites/ariannajohnson/2024/06/05/increasing-evidence-suggests-ozempic-semaglutide-helps-curb-alcoholism/ (accessed October 2, 2024).

King, A., A. Vena, D. S. Hasin, H. DeWit, S. J. O’Connor, and D. Cao. 2021. Subjective responses to alcohol in the development and maintenance of alcohol use disorder. American Journal of Psychiatry 178(6):560–571.

Klausen, M. K., M. E. Jensen, M. Møller, N. Le Dous, A. Ø. Jensen, V. A. Zeeman, C. F. Johannsen, A. Lee, G. K. Thomsen, J. Macoveanu, P. M. Fisher, M. P. Gillum, N. R. Jørgensen, M. L. Bergmann, H. Enghusen Poulsen, U. Becker, J. J. Holst, H. Benveniste, N. D. Volkow, S. Vollstädt-Klein, K. W. Miskowiak, C. T. Ekstrøm, G. M. Knudsen, T. Vilsbøll, and A. Fink-Jensen. 2022. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight 7(19):e159863.

Konanur, V. R., T. M. Hsu, S. E. Kanoski, M. R. Hayes, and M. R. Roitman. 2020. Phasic dopamine responses to a food-predictive cue are suppressed by the glucagon-like peptide-1 receptor agonist exendin-4. Physiology & Behavior 215:112771.

Kooij, K. L., D. I. Koster, E. Eeltink, M. Luijendijk, L. Drost, F. Ducrocq, and R. A.H. Adan. 2024. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neuroscience Applied 3:103925.

Kopp, K. O., E. J. Glotfelty, Y. Li, and N. H. Greig. 2022. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacological Research 186:106550.

Kopp, K. O., E. J. Glotfelty, Y. Li, D. K. Lahiri, and N. H. Greig. 2024. Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far? Ageing Research Reviews 98:102343.

Krajnc, N., B. Itariu, S. Macher, W. Marik, J. Harreiter, M. Michl, K. Novak, C. Wöber, B. Pemp, and G. Bsteh. 2023. Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. Journal of Headache and Pain 24(1):89.

Lawrence, E. C. N., M. Guo, T. D. Schwartz, J. Wu, J. Lu, S. Nikonov, J. K. Sterling, and Q. N. Cui. 2023. Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma. Frontiers in Cellular Neuroscience 17:1156829.

Leggio, L., C. S. Hendershot, M. Farokhnia, A. Fink-Jensen, M. K. Klausen, J. P. Schacht, and W. K. Simmons. 2023. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nature Medicine 29(12):2993–2995.

Leshner, A. I. 1997. Addiction is a brain disease, and it matters. Science 278(5335):45–47.

Leslie, M. 2023. Hot weight loss drugs tested against addiction. Science 381(6661):930–931.

Li, Y., T. Perry, M. S. Kindy, B. K. Harvey, D. Tweedie, H. W. Holloway, K. Powers, H. Shen, J. M. Egan, K. Sambamurti, A. Brossi, D. K. Lahiri, M. P. Mattson, B. J. Hoffer, Y. Wang, and N. H. Greig. 2009. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academies of Sciences 106:1285–1290.

Lincoff, A. M., K. Brown-Frandsen, H. M. Colhoun, J. Deanfield, S. S. Emerson, S. Esbjerg, S. Hardt-Lindberg, G. K. Hovingh, S. E. Kahn, and R. F. Kushner. 2023. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine 389(24):2221–2232.

Love, A., D. James, and P. Willner. 1998. A comparison of two alcohol craving questionnaires. Addiction 93(7):1091–1102.

Lu, Z., N. Percie Du Sert, S. W. Chan, C. K. Yeung, G. Lin, D. T. Yew, P. L. Andrews, and J. A. Rudd. 2014. Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. Journal of Translational Medicine 12:327.

Malatt, C., T. Wu, C. Bresee, E. J. Hogg, J. C. Wertheimer, E. Tan, H. Pomeroy, G. Obialisi, and M. Tagliati. 2022. Liraglutide improves non-motor function and activities of daily living in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Neurology 98(18 Suppl.):3068.

Maniscalco, J. W., and L. Rinaman. 2018. Vagal interoceptive modulation of motivated behavior. Physiology (Bethesda) 33(2):151–167.

McClean, P. L., V. Parthsarathy, E. Faivre, and C. Hölscher. 2011. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. Journal of Neuroscience 31(17):6587–6594.

McElroy, S. L., A. I. Guerdjikova, N. Mori, and A. M. O’Melia. 2012. Pharmacological management of binge eating disorder: Current and emerging treatment options. Therapeutics and Clinical Risk Management 8:219–241.

McElroy, S. L., S. J. Winham, A. B. Cuellar-Barboza, C. L. Colby, A. M. Ho, H. Sicotte, B. R. Larrabee, S. Crow, M. A. Frye, and J. M. Biernacka. 2018. Bipolar disorder with binge eating behavior: A genome-wide association study implicates PRR5-ARHGAP8. Translational Psychiatry 8(1):40.

McElroy, S. L., A. I. Guerdjikova, T. J. Blom, N. Mori, and F. Romo-Nava. 2024. Liraglutide in obese or overweight individuals with stable bipolar disorder. Journal of Clinical Psychopharmacology 44(2):89–95.

McGarry, A., S. Rosanbalm, M. Leinonen, C. W. Olanow, D. To, A. Bell, D. Lee, J. Chang, J. Dubow, R. Dhall, D. Burdick, S. Parashos, J. Feuerstein, J. Quinn, R. Pahwa, M. Afshari, A. Ramirez-Zamora, K. Chou, A. Tarakad, C. Luca, K. Klos, Y. Bordelon, M. H. St Hiliare, D. Shprecher, S. Lee, T. M. Dawson, V. Roschke, and K. Kieburtz. 2024. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson’s disease: A randomised, double-blind, placebo-controlled trial. The Lancet Neurology 23(1):37–45.

Meissner, W. G., P Remy, C. Giordana, D. Maltête, P. Derkinderen, J. L. Houéto, M. Anheim, I. Benatru, T. Boraud, C. Brefel-Courbon, N. Carrière, H. Catala, O. Colin, J. C. Corvol, P. Damier, E. Dellapina, D. Devos, S. Drapier, M. Fabbri, V. Ferrier, A. Foubert-Samier, S. Frismand-Kryloff, A. Georget, C. Germain, S. Grimaldi, C. Hardy, L. Hopes, P. Krystkowiak, B. Laurens, R. Lefaucheur, L. L. Mariani, A. Marques, C. Marse, F. Ory-Magne, V. Rigalleau, H. Salhi, A. Saubion, S. R. W. Stott, C. Thalamas, C. Thiriez, M. Tir, R. K. Wyse, A. Benard, O. Rascol; and the LIXIPARK Study Group. 2024. Trial of lixisenatide in early Parkinson’s disease. New England Journal of Medicine 390(13):1176–1185.

Mietlicki-Baase, E. G, P. I. Ortinski, L. E. Rupprecht, D. R. Olivos, A. L. Alhadeff, R. C. Pierce, and M. R. Hayes. 2013. The food intake-suppressive effects of glucagon-like peptide-1 receptor signaling in the ventral tegmental area are mediated by AMPA/kainate receptors. American Journal of Physiology–Endocrinology and Metabolism 305(11):E1367–E1374.

Mitchell, J. L., H. S. Lyons, J. K. Walker, A. Yiangou, O. Grech, Z. Alimajstorovic, N. H. Greig, Y. Li, G. Tsermoulas, K. Brock, S. P. Mollan, and A. J. Sinclair. 2023. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: A randomized clinical trial. Brain 146(5):1821–1830.

Mukherjee, A., A. Hum, T. J. Gustafson, and E. G. Mietlicki-Baase. 2020. Binge-like palatable food intake in rats reduces preproglucagon in the nucleus tractus solitarius. Physiology & Behavior 219:112830.

Müller, T. D., B. Finan, S. Bloom, D. D’Alessio, D. J. Drucker, P. Flatt, A. Fritsche, F. Gribble, H. Grill, and J. Habener. 2019. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism 30:72–130.

Niazi, S., F. Gnesin, A. S. Thein, J. R. Andreasen, A. Horwitz, Z. A. Mouhammad, B. N. Jawad, Z. Niazi, N. Pourhadi, B. Zareini, A. Meaidi, C. Torp-Pedersen, and M. Kolko. 2024. Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes. Ophthalmology 131(9):1056–1063.

Randolph, A. B., H. Zheng, and L. Rinaman. 2024. Populations of hindbrain glucagon-like peptide 1 (GLP1) neurons that innervate the hypothalamic PVH, thalamic PVT, or limbic forebrain BST have axon collaterals that reach all central regions innervated by GLP1 neurons. Journal of Neuroscience 44(31):e2063232024.

Resnick, B. 2024. Is Ozempic an anti-desire drug? Vox, May 7. https://www.vox.com/science/24086968/glp-1-ozempic-semaglutide-craving-desire-science-wanting-likingopioids-alcohol (accessed October 2, 2024).

Rhea, E. M., A. Babin, P. Thomas, M. Omer, R. Weaver, K. Hansen, W. A. Banks, and K. Talbot. 2023. Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases. Tissue Barriers, December 14. https://doi.org/10.1080/21688370.2023.2292461.

Richard, J. E., R. H. Anderberg, L. López-Ferreras, K. Olandersson, and K. P. Skibicka. 2016. Sex and estrogens alter the action of glucagon-like peptide-1 on reward. Biology of Sex Differences 7:1–16.

Robert, S. A., A. G. Rohana, S. A. Shah, K. Chinna, W. N. Wan Mohamud, and N. A. Kamaruddin. 2015. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide—A pilot study. Obesity Research & Clinical Practice 9(3):301–304.

Ryan, D. H., I. Lingvay, J. Deanfield, S. E. Kahn, E. Barros, B. Burguera, H. M. Colhoun, C. Cercato, D. Dicker, and D. B. Horn. 2024. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine 30:2049–2057.

Salameh, T. S., E. M. Rhea, K. Talbot, and W. A. Banks. 2020. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics. Biochemical Pharmacology 180:114187.

Sallis, J. F., and K. Glanz. 2009. Physical activity and food environments: Solutions to the obesity epidemic. Milbank Quarterly 87(1):123–154.

Scrocchi, L., T. Brown, N. MaClusky, P. Brubaker, A. Auerbach, A. Joyner, and D. Drucker. 1996. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Medicine 2(11):1254–1258.

Secher, A., J. Jelsing, A. F. Baquero, J. Hecksher-Sørensen, M. A. Cowley, L. S. Dalbøge, G. Hansen, K. L. Grove, C. Pyke, K. Raun, L. Schäffer, M. Tang-Christensen, S. Verma, B. M. Witgen, N. Vrang, and L. Bjerre Knudsen. 2014. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation 124(10):4473–4488.

Sherman, R. E., S. A. Anderson, G. J. Dal Pan, G. W. Gray, T. Gross, N. L. Hunter, L. LaVange, D. Marinac-Dabic, P. W. Marks, M. A. Robb, J. Shuren, R. Temple, J. Woodcock, L. Q. Yue, and R. M. Califf. 2016. Real-world evidence—What is it and what can it tell us? New England Journal of Medicine 375(23):2293–2297.

Sterling, J. K., M. O. Adetunji, S. Guttha, A. R. Bargoud, K. E. Uyhazi, A. G. Ross, J. L. Dunaief, and Q. N. Cui. 2020. GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension. Cell Reports 33(5):108271.

Sterling, J., P. Hua, J. L. Dunaief, Q. N. Cui, and B. L. VanderBeek. 2023. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. British Journal of Ophthalmology 107(2):215–220.

Strain, W. D., O. Frenkel, M. A. James, L. A. Leiter, S. Rasmussen, P. M. Rothwell, M. S. Ripa, T. C. Truelsen, and M. Husain. 2022. Effects of semaglutide on stroke subtypes in type 2 diabetes: Post hoc analysis of the randomized sustain 6 and pioneer 6. Stroke 53(9):2749–2757.

Svenningsson, P., K. Wirdefeldt, L. Yin, F. Fang, I. Markaki, S. Efendic, and J. F. Ludvigsson. 2016. Reduced incidence of Parkinson’s disease after dipeptidyl peptidase-4 inhibitors—A nationwide case-control study. Movement Disorders 31(9):1422–1423.

Tang, H., Y. Lu, M. S. Okun, W. T. Donahoo, A. Ramirez-Zamora, F. Wang, Y. Huang, M. Armstrong, M. Svensson, B. A. Virnig, S. T. DeKosky, J. Bian, and J. Guo. 2024. Glucagon-like peptide-1 receptor agonists and risk of Parkinson’s disease in patients with type 2 diabetes: A population-based cohort study. Movement Disorders 39(11):1960–1970. https://doi.org/10.1002/mds.29992.

Tang-Christensen, M., P. Larsen, R. Goke, A. Fink-Jensen, D. Jessop, M. Møller, and S. Sheikh. 1996. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 271(4):R848–R856.

Tirrell, M. 2023. Weight-loss meds like Ozempic may help curb addictive behaviors, but drugmakers aren’t running trials to find out. CNN Health, June 1. https://www.cnn.com/2023/06/01/health/weight-loss-drugs-addictive-behaviors/ (accessed October 1, 2024).

Tuesta, L. M., Z. Chen, A. Duncan, C. D. Fowler, M. Ishikawa, B. R. Lee, X.-A. Liu, Q. Lu, M. Cameron, and M. R. Hayes. 2017. GLP-1 acts on habenular avoidance circuits to control nicotine intake. Nature Neuroscience 20(5):708–716.

Turton, M., D. O’Shea, I. Gunn, S. Beak, C. Edwards, K. Meeran, S. Choi, G. Taylor, M. Heath, and P. Lambert. 1996. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379(6560):69–72.

Udo, T., and C. M. Grilo. 2018. Prevalence and correlates of DSM-5-defined eating disorders in a nationally representative sample of U.S. adults. Biological Psychiatry 84(5):345–354.

Urbanik, L. A., N. K. Acharya, and P. S. Grigson. 2022. Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats. Brain Research Bulletin 189:155–162.

Urbanik, L. A., J. L. Booth, N. K. Acharya, B. B. Evans, and P. S. Grigson. 2025. Effect of acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, and estrus phase on cue- and drug-induced fentanyl seeking in female rats. Behavioural Pharmacology 36(1):16–29.

Vallöf, D., P. Maccioni, G. Colombo, M. Mandrapa, J. W. Jörnulf, E. Egecioglu, J. A. Engel, and E. Jerlhag. 2016. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addiction Biology 21(2):422–437.

Vallöf, D., J. Vestlund, and E. Jerlhag. 2019. Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents. Neuropharmacology 149:124–132.

Vallöf, D., A. L. Kalafateli, and E. Jerlhag. 2020. Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats. Translational Psychiatry 10(1):238.

Villarejo, C., F. Fernández-Aranda, S. Jiménez-Murcia, E. Peñas-Lledó, R. Granero, E. Penelo, F. J. Tinahones, C. Sancho, N. Vilarrasa, M. Montserrat-Gil de Bernabé, F. F. Casanueva, J. M. Fernández-Real, G. Frühbeck, R. De la Torre, J. Treasure, C. Botella, and J. M. Menchón. 2012. Lifetime obesity in patients with eating disorders: Increasing prevalence, clinical and personality correlates. European Eating Disorders Review 20(3):250–254.

Volkow, N. D., G. F. Koob, and A. T. McLellan. 2016. Neurobiologic advances from the brain disease model of addiction. New England Journal of Medicine 374(4):363–371.

Wadden, T. A., A. M. Chao, S. Machineni, R. Kushner, J. Ard, G. Srivastava, B. Halpern, S. Zhang, J. Chen, and M. C. Bunck. 2023. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The surmount-3 phase 3 trial. Nature Medicine 29(11):2909–2918.

Waldrop, S. W., V. R. Johnson, and F. C. Stanford. 2024. Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity. Nature Medicine 30(1):22–25.

Wang, V., T. T. Kuo, E. Y. Huang, K. H. Ma, Y. C. Chou, Z. Y. Fu, L. W. Lai, J. Jung, H. I. Choi, D. S. Choi, Y. Li, L. Olson, N. H. Greig, B. J. Hoffer, and Y. H. Chen. 2021. Sustained release GLP-1 agonist PT320 delays disease progression in a mouse model of Parkinson’s disease. ACS Pharmacology & Translational Science 4(2):858–869.

Wang, W., N. D. Volkow, N. A. Berger, P. B. Davis, D. C. Kaelber, and R. Xu. 2024a. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications 15:4548.

Wang, W., N. D. Volkow, N. A. Berger, P. B. Davis, D. C. Kaelber, and R. Xu. 2024b. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: A retrospective cohort study. Molecular Psychiatry 29(8):2587–2598.

Wang, W., N. D. Volkow, N. A. Berger, P. B. Davis, D. C. Kaelber, and R. Xu. 2024c. Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: Target trial emulation using real-world data. Annals of Internal Medicine 177(8):1016–1027.

Wang, W., N. D. Volkow, Q. Wang, N. A. Berger, P. B. Davis, D. C. Kaelber, and R. Xu. 2024d. Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder. JAMA Network Open 7(9):e2435247.

Wang, W., N. D. Volkow, N. A. Berger, P. B. Davis, D. C. Kaelber, and R. Xu. 2024e. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine 30:168–176.

Wilding, J. P., R. L. Batterham, M. Davies, L. F. Van Gaal, K. Kandler, K. Konakli, I. Lingvay, B. M. McGowan, T. K. Oral, and J. Rosenstock. 2022. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The step 1 trial extension. Diabetes, Obesity and Metabolism 24(8):1553–1564.

Wong, C. K., B. A. McLean, L. L. Baggio, J. A. Koehler, R. Hammoud, N. Rittig, J. M. Yabut, R. J. Seeley, T. J. Brown, and D. J. Drucker. 2024. Central glucagon-like peptide 1 receptor activation inhibits toll-like receptor agonist-induced inflammation. Cell Metabolism 36(1):130–143. e135.

Yamaguchi, E., Y. Yasoshima, and T. Shimura. 2017. Systemic administration of anorexic gut peptide hormones impairs hedonic-driven sucrose consumption in mice. Physiology & Behavior 171:158–164.

Yun, S. P., T. I. Kam, N. Panicker, S. Kim, Y. Oh, J. S. Park, S. H. Kwon, Y. J. Park, S. S. Karuppagounder, H. Park, S. Kim, N. Oh, N. A. Kim, S. Lee, S. Brahmachari, X. Mao, J. H. Lee, M. Kumar, D. An, S. U. Kang, Y. Lee, K. C. Lee, D. H. Na, D. Kim, S. H. Lee, V. V. Roschke, S. A. Liddelow, Z. Mari, B. A. Barres, V. L. Dawson, S. Lee, T. M. Dawson, and H. S. Ko. 2018. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nature Medicine 24(7):931–938.

Zang, C., H. Zhang, J. Xu, H. Zhang, S. Fouladvand, S. Havaldar, F. Cheng, K. Chen, Y. Chen, B. S. Glicksberg, J. Chen, J. Bian, and F. Wang. 2023. High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data. Nature Communications 14(1):8180.

Zhang, J., T. Yi, S. Cheng, and S. Zhang. 2020. Glucagon-like peptide-1 receptor agonist exendin-4 improves neurological outcomes by attenuating TBI-induced inflammatory responses and MAPK activation in rats. International Immunopharmacology 86:106715.